19:47 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Dec. 19 that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon...
22:40 , Dec 19, 2018 |  BC Extra  |  Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Wednesday that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon is...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Financial News

Nexvet completes venture financing

Nexvet Biopharma , Melbourne, Australia   Business: Veterinary   Date completed: 4/16/14   Type: Venture financing   Raised: $31.5 million   Investors: Farallon Capital Management; Adage Capital Partners; Foresite Capital; Tavistock Life Sciences; existing investors...
07:00 , Mar 10, 2014 |  BioCentury  |  Finance

Innovator capital rationing

Conventional wisdom says VCs don't fund research-stage companies, but the numbers - and investors who play in the space - tell a different story. Since the financial meltdown, companies with a lead program in discovery...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Financial News

Calithera Biosciences completes venture financing

Calithera Biosciences Inc. , South San Francisco, Calif.   Business: Cancer   Date completed: 10/29/13   Type: Venture financing   Raised: $35 million   Investors: Adage Capital Partners; Longwood Fund; Morgenthaler Ventures; Advanced Technology Ventures;...
08:00 , Nov 4, 2013 |  BioCentury  |  Finance

Calithera metabolizes

Calithera Biosciences Inc. has reinvented itself as a cancer metabolism play since it last raised money. A strong belief in the company's management lured back at least one existing investor in last week's $35 million...
00:53 , Oct 30, 2013 |  BC Extra  |  Financial News

Cancer play Calithera raises $35M

Calithera Biosciences Inc. (South San Francisco, Calif.) raised $35 million in a series D round led by new investor Adage Capital Partners. New investors the Longwood Fund and two undisclosed institutional investors also participated, along...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Financial News

Ultragenyx completes venture financing

Ultragenyx Pharmaceutical Inc. , Novato, Calif.   Business: Musculoskeletal, Endocrine/Metabolic   Date completed: 12/20/12   Type: Venture financing   Raised: $75 million   Investors: Adage Capital Partners; T. Rowe Price; Jennison Associates; BlackRock BioCapital; Sanofi-Genzyme...
02:06 , Dec 21, 2012 |  BC Extra  |  Top Story

Ultragenyx raises $75 million in series B

Rare disease company Ultragenyx Pharmaceutical Inc. (Novato, Calif.) raised $75 million in a series B round led by new investor Adage Capital Partners. New investors T. Rowe Price; Jennison Associates; BlackRock BioCapital; Sanofi-Genzyme BioVentures; and...
08:00 , Jan 16, 2012 |  BioCentury  |  Finance

IPO end around

A trio of companies with ties to prostate cancer company Cougar Biotechnology Inc. have turned to the Form 10 pathway to list on U.S. markets at a time when biotech IPOs are difficult to complete....